Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SGN -- face to face due diligence. Actually I went behind the company to find credibility and authentication of identity.
1) I introduced the Signalife web page to several cardiologist. A few are known OPEN HEART surgeons in this Upstate New York region.
===================================================== =====
2) Cardiologist were familiar with Dr. Zachariah P. Zachariah of Ft. Lauderdale, Florida who recently was appointed as a medical and business consultant to the Company
===================================================== ==
3) All the cardiologist who viewed the breakthrough in the cardiac monitoring were simply impressed. They were impressed with the Technology Breakthrough page. http://www.signalife.com/Pages/What-Card...
=============================================
Zachariah - outstanding consistent articles
http://www.highbeam.com/search.aspx?q=Zachariah&ref_id=ency_botnm
===================================================
Zachariah Family Wellness Pavilion
http://www.holy-cross.com/wellness/index.php?page=homePage
================================================================
To draw a big name like Zachariah into your organization. YOU BEST HAVE THE GOODS!
=============================================================
$400 billion cardiac disease market! SGN will likely take a portion of it. Very possibly, Huntleigh will be the SGN partner.
http://www.huntleigh-technology.com/huntleigh/investors/index.jsp
Huntleigh is a major international company serving the global healthcare market with high quality medical equipment. 2000 employees in 120 countries.
============================================================
SIGNALIFE INC (AMEX:SGN)
http://finance.yahoo.com/q?s=SGN
SGN - 660 pt drop suppressed the news
My theory on shallow share price is simple. When the Huntleigh-Technology, PLC news broke it was made in the suppressive 660 point market drop. SGN nevertheless managed to gain a few percentages. If it had not been for the 600 pt market drop suppression. I totally believe the stock could have reached to the $4 level. Todays after-market is indication that investors are back reviewing what they missed.
----------------------------------------------------- ----
My theory I feel is strong. Take a look at NYMX on the day it announced negotiations. NYMX had no 600 point market drop depression to contend with.
===================================================== =====
SGN's, algorithmic and digital form of dry metal electrodes for use in ECG equipment is simply astronomical.
Every medical service facility is a customer across all of North America.
Huntleigh-Technology, PLC may make an equity investment. A licensure agreement payment could very well see a 100 million dollars on a term payment. I know these Cardiac electrodes are used like candy in most medical facilities. The savings in labor by the added convenience is astronomical.
===================================================== ====
Anyhow not to get off on a tangent. I believe my theory is sound in regards to the price of the stock.
================================================================
disclaimer: I do own SGN
SIGNALIFE INC (AMEX:SGN) After market is already up 2.45%
SGN looking like it wants to make another jab at going higher here...just waiting for a little more volume to start coming in....soon I hope.
yea, good little trader, out over $2, want back in if it can break 1.90 or so.
Signalife 'Perfects' Dry Metal Electrode for ECGs
GREENVILLE, S.C., Feb. 7 /PRNewswire-FirstCall/ --Signalife, Inc. (Amex: SGN). Signalife, Inc. announced today that it has 'perfected' - both in algorithmic and digital form - the utilization of dry metal electrodes for use in its ECG equipment. While the current Fidelity 100 still uses conventional electrodes as required under industry standards, the Company's SHC ('Heart Credit Card') utilizes dry metal electrodes and the Company had always planned to expand the use of dry, convenient and painless metal electrodes in its other devices. That utilization has now been 'perfected' in the Company's Los Angeles laboratories. Several new ECG devices - including holter monitors and various smaller and more convenient and portable devices - will flow from the ability to obtain the Company's flawless ECG signal with a painless metal electrode that merely touches the patient's chest. The electrode is the size and constituency of a quarter.
The Company's Chief Technology Officer, Budimir Drakulic, commented that 'the presence of dry electrodes is critical to assuring patient compliance in utilizing their ECGs.' The renown micro-electronics engineer also underscored the fact that 'with the lesser and more removed patient electrode, we now have a situation where other ECG devices cannot achieve any signal whatsoever (there is no 'stick on' electrode to connect to the patient's chest) whereas the Signalife machines continue to achieve a flawless ECG signal.' Dr. Drakulic added: 'This is similar to our vest, but is far more flexible and adaptable to a myriad of other devices and uses - both inside the health care facility and in the real world.'
The Company underscores that the medical standard of care - for its flagship Fidelity 100 device - continues to have the appearance of requiring traditional 'stick on' electrodes. Rather, the dry metal electrodes are expected to pave the way for Signalife's entire line of additional products that can allow the patient to gain an entree' into his or her 'heart health' without the necessity of a full, 12-lead ECG test.
The utilization of these components, as with all medical devices and associated apparatus, must comply with various regulatory requirements and - in certain instances - clear certain regulatory hurdles. The Company does not view these as significant or time consuming, and will assure clearance in the ordinary course of its business.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Watch what happens after the stock retraces...this was to be expected after that huge run up..once it breaths it will regain its composure and take the next leg...UP.
Lebed is not giving the normal !!!!!!!!!! which means he is not fully behind this stock. He only gave !!!
Lebed email:
I am convinced that SGN will be the BIGGEST play on the entire AMEX next week.
I have a feeling that something HUGE is about to happen.
Of course, this is only my opinion. Do not listen to me. Do your own research and make your own investment decisions.
Watch SGN like a hawk and do not take your eyes off of it!!!
As I now understand it Ledbed is now behind SGN. I think he was paid in cash and not stock which means he is solidly behind the stock and not in front of it.
Good things on the way me thinks.
SGN had a nice write up on http://www.antandsons.com/ on Jan 26th which is quickly becoming an understatement in performance of the stock....here it is:
January 26, 2007
Signalife Heads Towards $2.00 Breakout
Late this morning, Signalife, Inc. (AMEX: SGN) announced that it completed the development of a prototype device to be utilized for objective evaluation of ECG/IC (Electrocardiogram and Intracardiac) data Recorders. The stock had drifted lower for the latter part of 2006. Earlier this year, the stock finally came up for air after it unveiled its one-of-a-kind cardiac vest that uses the company's technology to allow for ECG monitoring of athletes and patients in harsh ambulatory environments. Shares have nearly doubled since that time. The stock is now nearing tough resistance of $2.00, doing so on the back of today's news and good accumulation of Signalife shares. Volume is about one and a half times the average at 332,600 shares.
Can you say "Resistance is futile?"
Rob what is the reason for spamming this stock all over IHUB? It bothers me when I see that it diminishes what the stock is all about and IHUB for that matter.
Please don't do that...SGN is a good stock and will do fine without it.
Thank You
Amazing action. Loving every second of this.
I know he was on it then off it....is he back on now?
He should be..lol
Stock is up 100% since he mentioned it.
Sorry didn't check email for a while....Ice Man on SGN.
http://www.icecoldstocks.net/
The short number comes from a very reliable source.
As far as selling after seeing the follow through in trading smart money got back in...I know I did.
And yes I think short or long term is going to be beneficial in any case....time will tell the tail as always.
I am expecting many good things to come for this company...its overdue.
Where did u get that short numbers.
I really like this company and looks like a year from now you guys would look back and think you made a mistake by selling this one.
Keep it in your IRA portfolio
Going much higher me thinks...lots a stuff going on with this company.
What I am looking for right now is the short situation to kick into high gear...thats getting very close right now and I think there is a lot of pressure on them as we speak.
5 million shares are short.
Its seems to be working on it..lol
Big 5 million share short position is gonna help things a lot when the shorts get to their gag position.
When the margin calls start coming in we will know and that hasn't happened yet.
Things starting to heat up again..showing good strength and trend is setting up nicely.
Signalife's 'Credit Card' Personal Event Monitor
Jan 23, 2007 11:30:00 AM
GREENVILLE, S.C., Jan. 23 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN), the revolutionary heart monitoring company, announced today that it has completed design and manufacturing specifications for fabrication of its state-of-the-art "personal" event monitor. The device, which is essentially the size of a "credit card," utilizes a micro-engineered version of the Company's patented "patient module" found in the flagship "Fidelity 100" product currently being distributed. The difference between the two devices is that the "Fidelity 100" utilizes the clinical standard of 12-leads for hospital, surgical and other standard medical environments. The "personal event monitor" -- called the "Signalife Heart Card" ("SHC") -- is held over the center of a patient's chest to detect cardiac status. A patient can carry the SHC in his wallet and pull it out at any time in order to monitor the cardiac signal emanating from his chest, for transmission and review by monitoring centers or physicians.
The Company has been developing the SHC for some time, and the fabrication specifications are of critical importance in view of the size and configuration of the device. Extensive testing was completed by the company in order to validate the precise specifications, and enable regulatory and manufacturing work to now be completed. It is anticipated that the device will be ready for full scale distribution in the third quarter of this year.
Budimir S. Drakulic, the Company's CTO, stated: "To have met this milestone in a timely manner is very exciting for the Company. I must congratulate our R&D team for hard work, vigorous testing and analysis that has gone into these fabrication models. When people in our society are able to access the use of our patented award winning "patient module" in over-the- counter settings (i.e., without prescription), the opportunity for cardiac disease evaluation and subsequent opportunity of prevention is obviously maximized."
The SHC must still pass regulatory approval, and subsequent testing as well as other scientific and manufacturing regulatory hurdles. The Company is confident that these will be timely accomplished and is looking forward to movement toward the marketplace.
About Signalife
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company's website is available at: http://www.signalife.com
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife, Inc. results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approval governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife's products or services, adverse equity market conditions and declines in the value of Signalife's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
PRESS RELEASE
Thursday January 18, 2007
Signalife Cardio Gym Up and Running At Gold’s Gym
GREENVILLE, S.C., January 18, 2007 /PRNewswire-FirstCall/ -- Signalife, Inc. ("Company"), (Amex: SGN - News) announced today that cardiac exercise testing has begun at Gold’s Gym utilizing the Company’s Fidelity 100. The testing has begun at the original Gold’s Gym in Venice Beach, California, known as the “mecca.” The test is available for all members of the Venice Beach Gold’s Gym facility and is conducted numerous times daily for a fee. The protocol for the cardiac screening exam has been established and evaluated by physicians in the area that also monitor the results for the clientele.
“It is exciting to see the gym clientele embrace a better understanding of their cardiac health in an environment where they already go to exercise and to focus on their fitness. I was pleased to be onsite for the initial tests and to witness the enthusiasm expressed by the gym clientele,” stated Pamela Bunes, CEO and President of Signalife, Inc.
Picture of Golds gym setup: http://www.signalife.com/images/CardioGym.jpg
About Signalife, Inc.
Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient’s cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit http://www.signalife.com.
I also expected a pull back after the large gain now it's steady it should slowly move north from here.
I think my entry point was good.
I can't predict the bottom all the time but can come close.
Do you think this is going to make a big run in the short term?
Seems to have stabilized very well today with lots of accumulation taking place. That was a big move yesterday had me a little worried, now we can settle down and take smaller steps. I like nice and easy anyway.
In at 1.26 just 2k I knew there would be a shake!
Now we can see how strong that bid really is!
SGN US A Bid + 1.40 Ask 1.42 Last 1.40 -0.01 354,600
Bid Size 344 Ask Size 7
I will be grabbing some today I think around 10.20am would be the best time to jump in.
Let's make some cash !!!
it looks good HC. Cowboy's going to be the man on this one. I think we are going to be "in the loop" .. it doesn't take a genius to see 2.50 on this.
Looks like the shorts are going to be fried!
Tomorrow should be a great day!
Goodluck!
Yaaa...not tooo shabby eh..lol
How about that volume! Wow, something happening here. /e
Happy do some Due Diligence and you can buy carefully..lol
I expect a battle with the shorts tomorrow but should shoot up as they get out.
I like the graft and charts on this one
I will be watching this one carefully.
Which Iceman are you talking about? And was that on IHUB or another board?
Can you provide a link please.
I am in today, based on Iceman's comments, and the company's potential....
Great Video on their product:
http://www.signalife.com/Pages/videoWMV-AHA06.html
Signalife Completes Long-Awaited Cardiac Vest
Monday January 8, 8:58 am ET
GREENVILLE, S.C., Jan. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News), the revolutionary heart monitoring company, announced today that it has completed -- for fabrication and ultimate distribution -- its one-of-a-kind cardiac vest that utilizes Signalife's patented signal amplification technology to allow for precise ECG monitoring of athletes and patients in harsh ambulatory environments.
ADVERTISEMENT
The cardiac vest, featured on November 30, 2006 in an NBC Today Show's segment ("Modern Medical Miracles"), has been extensively utilized in testing in the Champ Car World Series open cockpit racing. During these tests, the ECG signals have allowed physicians to evaluate data previously unavailable when captured in the very harsh environment of a race car.
In present cardiac devices, noise and artifact distort ECG recordings in an ambulatory setting. In addition, uncomfortable sticky electrodes are placed on the patient's torso prior to testing. Skin preparation, which may include shaving hair or skin abrading, is often necessary without the Signalife vest. The Signalife proprietary vest features dry (e.g., quarter-size, metal) electrodes embedded in a cloth fabric which provide better comfort and reduced skin irritation for a large percentage of the clients or patients.
Signalife is aware of no other system that can acquire a similar ECG signal in any ambulatory environment with the use the metal electrodes compatible with Signalife's cardiac vest.
With these approvals, Signalife will now proceed to submit the vest for accelerated FDA clearance and rapid movement into the marketplace. The completion of the cardiac vest coincides with Signalife's business plans to "time" its Gold's Gym initiative with the Company's other exercise programs. The first Gold's Gym facility is fully built out, complete with -- among other things -- the cardiac center and other tools to assist the clientele and physicians in screening related to inherent cardiovascular health fitness.
Budimir Drakulic, the Company's Chief Technology Officer, indicated that he was "very satisfied with the development of the vest and its performance during the Champ Car testing." Dr. Drakulic said: "Given the difficulty surrounding the recording of electrocardiographic data during car races, Signalife's R&D team -- and particularly Marko Kostic, the Company's Champ Car project leader -- deserves praise for the successful development of the cardiac vest and accompanying systems.
The performance of the vest can be witnessed on video within Signalife's website, www.signalife.com, or by clicking on http://www.msnbc.msn.com/id/3032633/.
About Signalife
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company's website is available at: http://www.signalife.com
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife, Inc. results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approval governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife's products or services, adverse equity market conditions and declines in the value of Signalife's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
Source: Signalife, Inc.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
192
|
Created
|
01/08/07
|
Type
|
Free
|
Moderators |
PLEASE READ THE RECENT LAWSUIT NEWS RELEASE.
Junk Faxes to Promote Stock; Signalife Loses Lawsuit
http://www.knobias.com/story.htm?eid=3.1.f275d1b75a8b45267c5519ae04a78b714e97f420528599f5ebdbe706f2dfd505
Peter Strojnik, P.C. Files First Amended Complaint Alleging Signalife, Inc. Engaged in Mass Broadcasting of Junk Faxes to Promote Its Stock; Signalife Loses Strojnik Lawsuit
Wednesday, November 05, 2008 12:30ET
PHOENIX, Nov 05, 2008 (BUSINESS WIRE) -- On October 7, 2008, Peter Strojnik, P.C. filed a first amended complaint in its proposed class action lawsuit against Signalife, Inc. in the United States District Court for the District of Arizona, case number 2:08-cv-1116, alleging the medical supply company engaged in a mass-broadcast of junk faxes to promote its stock.
President and CEO of Peter Strojnik, P.C., Peter Strojnik, opined that Signalife certainly has a motive to pump up the price of their stock. The Complaint alleges "Signalife had a net loss for the six months ending June 20, 2008 in the amount of $8,826,795.00." Mr. Strojnik added, "Signalife admitted in a recent Form 10Q that they had no revenues from product sales during the first half of 2008." Indeed, the Complaint alleges "Signalife has no sales revenues and admits ... that its inability to generate revenues could cause it to go out of business."
Signalife has not gone out of business, but they have been delisted from the American Stock Exchange. In fact, Signalife recently affected a 4500 for 1 reverse stock split and started trading on the OTCBB and Pink Sheets.
Mr. Strojnik explained that the Telephone Consumer Protection Act awards damages at a minimum of $500 for each unsolicited fax. The proposed class action lawsuit against Signalife and others alleges Defendants broadcasted between approximately 12 million to 16 million unsolicited faxes.
In what Mr. Strojnik opined was a defense tactic, Signalife, Inc. filed a Complaint for Declaratory Relief against Peter Strojnik, P.C. in Los Angeles. Signalife sought a decree that it did not violate the TCPA. After several months of argument and deliberations, Orange County Superior Court dismissed the case.
Peter Strojnik, P.C.'s proposed class action lawsuit alleges that "The purpose of the Unsolicited Fax was to manipulate SGN stock or any publicly traded Signalife stock in the securities market." Mr. Strojnik opined, "Signalife cannot be allowed to violate federal law without redress for the regular people who receive these annoying faxes." Paraphrasing the allegations of the Complaint, Mr. Strojnik stated, "In my opinion, Signalife or its insiders hired a third party fax blaster to broadcast millions of faxes promoting its stock." Indeed, Signalife admits in its most recent Form 10Q that they are "in discussions with a number of large third party marketing and distribution partners with the manpower and financial resources to more quickly and aggressively promote [its] products."
Other defendants in the class action lawsuit include Digitalspeed Communications, Inc. and Adam Harris Pasternack.
For more information, please contact Peter Strojnik at ps@strojnik.com or at (602) 524-6602.
SOURCE: Peter Strojnik, P.C.
Peter Strojnik, P.C.
Peter Strojnik, 602-524-6602
ps@strojnik.com
Copyright Business Wire 2008
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |